Alvespimycin
Information
- Drug Name
- Alvespimycin
- Description
- Entry(CIViC)
- 3
CIViC
| Disease | Mutation | EL | ET | ED | CS | VO | TR | Pubmed | Links |
|---|---|---|---|---|---|---|---|---|---|
| lung non-small cell carcinoma | ALK EML4-ALK E20;A20 | D |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 2 | 22912387 | Detail |
| lung non-small cell carcinoma | ALK EML4-ALK E6;A20 | D |
Predictive
|
Does Not Support
|
Sensitivity/Response | Somatic | 2 | 22912387 | Detail |
| lung non-small cell carcinoma | ALK EML4-ALK | D |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 2 | 22912387 | Detail |
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| EML4-ALK fusions occur in 2-7% of lung adenocarcin... | ALK | ALK EML4-ALK E20;A20 | Sensitivity | true | CIViC Evidence | detail |
| Transduction of Ba/F3 cells with EML4-ALK variant ... | ALK | ALK EML4-ALK E6;A20 | Sensitivity | false | CIViC Evidence | detail |
| Transduction of Ba/F3 cells with EML4-ALK variant ... | ALK | ALK EML4-ALK | Sensitivity | true | CIViC Evidence | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT00803556 | Completed | Phase 1 | Clinical Trial of the Combination of Intravenous Alvespimycin (KOS-1022), Trastuzumab With or Without Paclitaxel in Patients With Advanced Solid Tumor Malignancies or Her2 Positive Metastatic Breast Cancer Who Have Previously Failed Trastuzumab Therapy | January 2006 | August 2009 |
| NCT00780000 | Terminated | Phase 2 | Clinical Trial of Intravenous Alvespimycin in Patients With Her2 Positive Breast Cancer | April 2008 | June 2008 |